Overview

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Status:
NOT_YET_RECRUITING
Trial end date:
2030-06-18
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen
Treatments:
blinatumomab